What was the primary reason for this 8-K filing?

The primary reason for this 8-K filing was to announce that CME Group Inc. reached an agreement to resolve an indemnification dispute with Euronext-Paris S.A. concerning CME's settlement of the Wagner Patent litigation.

How much money will CME receive from Euronext-Paris S.A.?

CME will receive U.S. $7.5 million from Euronext-Paris S.A. as part of the resolution.

What was the original settlement amount CME paid, and how does this new agreement affect it?

CME originally settled the Wagner Patent litigation for $15 million in August 2002. The agreement with Euronext, under which CME receives $7.5 million, effectively means that CME's net cost for the settlement is reduced by half, to $7.5 million.

What is Regulation FD Disclosure?

Regulation FD (Fair Disclosure) is an SEC rule designed to prevent selective disclosure of material nonpublic information by public companies. Item 9 of the 8-K, Regulation FD Disclosure, indicates that the information provided is being publicly disseminated to avoid selective disclosure.

CME 8-K SEC Disclosure

Summary

CME Group Inc. (CME) has filed an 8-K report on January 3, 2003, to disclose the resolution of an indemnification dispute with Euronext-Paris S.A. This dispute stemmed from CME's $15 million settlement in August 2002 concerning the Wagner Patent litigation. The agreement reached is a significant development for CME, as it directly impacts the net cost of the patent litigation settlement. Under the terms of the new agreement, Euronext will pay CME $7.5 million. This payment effectively covers half of the total settlement amount previously paid by CME. Investors should view this as a positive development, as it reduces the financial burden on CME and improves its profitability related to this specific legal matter. The filing also includes the press release detailing this resolution as an exhibit.

Key Highlights

1CME Group Inc. resolved an indemnification dispute with Euronext-Paris S.A.
2The dispute was related to CME's $15 million settlement in August 2002 of the Wagner Patent litigation.
3Euronext-Paris S.A. will pay CME $7.5 million as part of the resolution.
4This payment represents half of CME's total settlement cost for the patent litigation.
5The filing was made on January 3, 2003, and announced via a press release.
6This agreement reduces the net financial impact of the patent litigation on CME.

CME GROUP INC. 8-K Report (Jan 3, 2003)

Summary

Key Highlights

Frequently Asked Questions